Pynstop 5mg / 10mg / 45mg / 450mg Tablet

    Pynstop 5mg / 10mg / 45mg / 450mg Tablet

    S2
    PDF Leaflet Revision Date: 26 April 2016


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Symptomatic relief of mild to moderate pain and fever.

    Dosage (summary)

    1-2 tablets every 4 hours as needed, max 8 tablets/day.

    Special Populations

    • Liver impairment
    • Kidney impairment

    Pregnancy & Breastfeeding

    Safety not established in pregnancy and lactation.

    Key Drug Interactions

    • Alcohol
    • CNS depressants
    • Monoamine oxidase inhibitors

    Contraindications

    • Allergy to ingredients
    • Severe liver impairment
    • Respiratory depression
    • Bronchial asthma
    • Heart failure
    • Head injuries
    • Acute alcoholism

    Common side effects

    • Nausea
    • Drowsiness
    • Constipation
    • Skin rashes
    • Gastrointestinal disturbances

    Counselling Points

    • Avoid driving or operating machinery
    • Consult doctor if no relief
    • Do not use continuously for more than 10 days

    Serious warnings

    • Risk of dependence and addiction
    • Caution in peptic ulcer
    • Do not exceed recommended dose
    Important Disclaimer

    The Pynstop 5mg / 10mg / 45mg / 450mg Tablet professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Clinical Particulars

    Section 4 of the official insert — extracted exactly as issued, no alterations

    4.1 Therapeutic indications

    PYNSTOP tablets for adults are indicated for the symptomatic relief of mild to moderate pain and pain associated with tension and fever.

    4.2 Posology and method of administration

    Adults and children over 12 years: One or two tablets repeated four hourly if necessary. Do not exceed eight tablets per day. Consult your doctor if no relief is obtained with the recommended dosage. Do not exceed the stated dose.

    4.3 Contraindications

    PYNSTOP tablets are contraindicated in: Sensitivity (allergy) to the active ingredients. Severe liver function impairment. Respiratory depression, especially in the presence of cyanosis and excessive bronchial secretion. During an attack of bronchial asthma. Heart failure secondary to lung disease. Head injuries and conditions in which intracranial pressure is raised. The presence of acute alcoholism. After operations on the biliary tract.

    4.4 Special warnings and precautions for use

    Codeine: Exceeding the prescribed dose, together with prolonged and continuous use of this medication may lead to dependence and addiction. Codeine should be given with extreme caution to patients taking monoamine oxidase inhibitors or within 14 days of stopping such treatment. Caffeine to be used with care by patients with a history of peptic ulceration. Large doses may precipitate fits in epileptics. Use with care in conditions such as glaucoma and prostatic hypertrophy. Patients should be warned against taking charge of vehicles or machinery or performing potentially hazardous tasks where loss of concentration may lead to accidents. Consult a doctor if no relief is obtained from the recommended dosage. Do not use continuously for more than 10 days without consulting your doctor. Dosages in excess of those recommended may cause severe liver damage. PYNSTOP tablets should not be given to children under 12 years of age. Patients suffering from liver or kidney disease should only take paracetamol under medical supervision.

    4.5 Interactions with other medicines

    This medicine may lead to drowsiness and impaired concentration that may be aggravated by simultaneous intake of alcohol or other central nervous system depressants. Doxylamine succinate may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and tranquillisers. The depressant effects of codeine are enhanced by depressants of the central nervous system such as alcohol, anaesthetics, hypnotics and sedatives.

    4.6 Fertility, pregnancy and lactation

    Safety of PYNSTOP in pregnant and lactating women has not been established.

    4.7 Effects on ability to drive and use machines

    Patients should be warned against taking charge of vehicles or machinery or performing potentially hazardous tasks where loss of concentration may lead to accidents.

    4.8 Undesirable effects

    Paracetamol: Side effects of paracetamol are usually mild though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia and agranulocytosis have been reported. Pancreatitis, skin rashes and other allergic reactions occur occasionally. The rash is usually erythematous or urticarial but sometimes more serious and may be accompanied by fever and mucosal lesions.

    Doxylamine succinate: Sedation may occur. Other side effects include gastrointestinal disturbances, blurred vision, tinnitus, elation or depression, irritability, nightmares, anorexia, difficulty in micturition, dryness of the mouth, tightness of the chest, and tingling, heaviness and weakness of the hands may occur. Symptoms of stimulation include insomnia, nervousness, tachycardia, tremors, muscle twitching and convulsions.

    Codeine phosphate: May cause nausea, vomiting, constipation, drowsiness, confusion, dry mouth, sweating, facial flushing, dizziness, slow pulse rate, low blood pressure when standing erect, subnormal body temperature, restlessness and changes of mood.

    Caffeine: Can cause the following side effects: nausea, headache, sleeplessness, irritability and symptoms of anxiety. Large doses may cause restlessness, excitement, muscle tremor, ringing of the ears, increased pulse rate and gastric ulceration.

    4.9 Overdose

    Paracetamol: In the event of overdosage or suspected overdose and notwithstanding the fact that the person may be asymptomatic, the nearest doctor, hospital or poison control centre must be contacted immediately. Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias have been reported. Symptoms during the first 2 days of acute poisoning do not reflect the potential seriousness of the overdosage. Nausea, vomiting, anorexia and abdominal pain may persist for a week or more. Liver injury may become manifest on the second day, (or later) initially by elevation of serum transaminase and lactic dehydrogenase activity, increased serum bilirubin concentration and prolongation of prothrombin time. The liver damage may progress to encephalopathy, coma and death. Cerebral oedema and non-specific myocardial depression have also occurred. In the event of overdosage consult your doctor or take the patient to the nearest hospital immediately. Specialised treatment is essential as soon as possible. Prompt treatment is essential. Any patient who has ingested 7,5 g of paracetamol in the preceding 4 hours should undergo gastric lavage. Specific therapy with an antidote such as acetylcysteine or methionine may be necessary. If decided upon, acetylcysteine should be administered IV as soon as possible. Acetylcysteine: Acetylcysteine should be administered as soon as possible, preferably within 8 hours of overdosage. IV: An initial dose of 150 mg/kg in 200 ml glucose injection, given intravenously over 15 minutes, followed by an intravenous infusion of 50 mg/kg in 500 ml of glucose injection over the next 4 hours and then 100 mg/kg in 1 000 ml over the next 16 hours. The volume of intravenous fluids should be modified for children. Orally: 140 mg/kg as a 5 % solution initially, followed by a 70 mg/kg solution every 4 hours for 17 doses. Acetylcysteine is effective if administered within 8 hours of overdosage. Doxylamine succinate, codeine phosphate and caffeine: Refer to u2018SIDE-EFFECTSu2019. Treatment is symptomatic and supportive.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites